{"id":829952,"date":"2025-03-26T08:11:52","date_gmt":"2025-03-26T12:11:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/"},"modified":"2025-03-26T08:11:52","modified_gmt":"2025-03-26T12:11:52","slug":"briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/","title":{"rendered":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference"},"content":{"rendered":"
\n

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th<\/sup> \u2013 30th<\/sup> at\u00a0McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR<\/em>.<\/p>\n

\n Poster 1: <\/strong>
\n
\n Title: <\/strong>
\n Bria-ABC<\/em>
\n
\n 1<\/em>
\n <\/sup> vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trial
Session Title: <\/strong>Late-Breaking Research: Clinical Research 4
Session Date and Time: <\/strong>4\/30\/2025 9:00 AM \u2013 12:00 PM CST
Location: <\/strong>Poster Section 49
Poster <\/strong>Board Number: 14
Abstract Presentation Number: <\/strong>LB408<\/p>\n

\n Poster 2: <\/strong>
\n
\n Title:<\/strong> Survival outcomes in a randomized phase 2 of Bria-IMT<\/em>: An allogeneic whole cell cancer vaccine
Session Title:<\/strong> Phase II and Phase III Clinical Trials
Session Start: <\/strong>4\/28\/2025 2:00 PM \u2013 5:00 PM CST
Location:<\/strong> Poster Section 50
Poster Board Number:<\/strong> 18
Abstract Presentation Number:<\/strong> CT100<\/p>\n

\n Poster 3: <\/strong>
\n
\n Title:<\/strong> Bria-OTS+: A versatile therapeutic platform for inducing anti-cancer immunity
Session Category:<\/strong> Immunology
Session Title:<\/strong> Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: <\/strong>4\/28\/2025 2:00 \u2013 5:00 PM CST
Location:<\/strong> Poster Section 39
Poster Board Number:<\/strong> 29
Published Abstract Number:<\/strong> 3553<\/p>\n

Following the presentation, copies of the posters will be made available at https:\/\/briacell.com\/scientific-publications\/<\/a>.<\/p>\n

\n About BriaCell Therapeutics Corp.<\/strong>\n <\/p>\n

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https:\/\/briacell.com\/<\/a>.<\/p>\n

\n Safe Harbor<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting three posters at the 2025 AACR, and the contents of such posters, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company’s most recent Management\u2019s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n

\n Contact Information<\/strong>\n <\/p>\n

\n Company Contact:<\/strong>
\n
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com<\/a>\u00a0<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
\n investors@briacell.com<\/a>\n <\/p>\n

\n

\n 1<\/sup> Bria-ABC refers to the pivotal Phase 3 Study entitled, Study of the Bria<\/u><\/em><\/strong>-IMT Regimen and CPI vs Physicians’ Choice in A<\/u><\/em><\/strong>dvanced Metastatic\u00a0B<\/u><\/em><\/strong>reast C<\/u><\/em><\/strong>ancer (BRIA-ABC) NCT06072612<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th \u2013 30th at\u00a0McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR. Poster 1: Title: Bria-ABC 1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trialSession Title: Late-Breaking Research: Clinical Research 4Session Date and Time: 4\/30\/2025 9:00 AM \u2013 … <\/p>\n

Continue reading “BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829952","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th \u2013 30th at\u00a0McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR. Poster 1: Title: Bria-ABC 1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trialSession Title: Late-Breaking Research: Clinical Research 4Session Date and Time: 4\/30\/2025 9:00 AM \u2013 … Continue reading "BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T12:11:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference\",\"datePublished\":\"2025-03-26T12:11:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/\"},\"wordCount\":597,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/\",\"name\":\"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=\",\"datePublished\":\"2025-03-26T12:11:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - Market Newsdesk","og_description":"PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th \u2013 30th at\u00a0McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR. Poster 1: Title: Bria-ABC 1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trialSession Title: Late-Breaking Research: Clinical Research 4Session Date and Time: 4\/30\/2025 9:00 AM \u2013 … Continue reading \"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-26T12:11:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference","datePublished":"2025-03-26T12:11:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/"},"wordCount":597,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/","name":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=","datePublished":"2025-03-26T12:11:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDg5OSM2ODM0MzQ4IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829952"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829952\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}